The Board of Directors of Genovis has announced that it has filed a lawsuit against Promega Corporation (“Promega”) for patent infringement regarding one of Promega’s products. The lawsuit includes an injunction to prevent Promega from producing, using, selling or offering for sale the infringing product, as well as damages. The suit was filed in the United State District Court of Delaware. Genovis develops, produces and markets innovative technologies that facilitate and enable development of new treatment methods, as well as diagnostics for the pharmaceutical industry. The suit relates to Promega’s new product IdeS Protease, which Genovis believes infringes US Patent No. 7.666.582 for which Genovis has an exclusive global license that expires in 2022 and covers Genovis’ product FabRICATOR®. Genovis has not provided any sublicense to Promega. “Pursuing legal action is time consuming, but at the same time it is important for Genovis to protect the intellectual property that belongs to the company and its shareholders. FabRICATOR® is the first product Genovis launched and has been sold with good growth in the U.S. market since 2009. The product has also helped to create markets for our other product launches to the world’s leading pharmaceutical companies. Genovis has insurance that covers most of the cost of the suit and I would like to point out that the patent infringement only applies to the U.S. market,” says Sarah Fredriksson, CEO of Genovis. Genovis’ customers include pharmaceutical and biotech companies, academia and regulatory authorities, including the FDA. They all use FabRICATOR to characterize antibody-based drugs. Modern biological pharmaceuticals against diseases such as cancer are frequently made of antibody molecules that require advanced technology to characterize and analyze them. Analysis is an important cornerstone prior to registration with regulatory authorities, as well as for quality control during production of the approved drug. FabRICATOR is extremely fast and accurate, which enables customers to use a new analytical technique that provides reliable, more easily interpreted results. Customers also save time and lower their analysis costs. For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com ABOUT GENOVIS Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North, and Consensus is Certified Adviser for the Company, t: 46 (0)31-745 50 00
Genovis AB sues US company for patent infringement The
Top 10 Most Recent News Articles
Stitch AI Targets Banking’s Hardest Automation Gap
The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...
Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand
A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...
Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves
A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...
Continue Reading
Rochester Truck Crashes Demand a Different Liability Map
An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...
Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets
Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...
Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test
A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...
Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth
Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...
Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence
Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...
Continue Reading
Parents Hand Kids Devices Years Before They Intended
A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...
Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further
Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...
Continue ReadingTop 5 Most Recently Viewed Articles
Liberty Media Corp Achieves Milestone with Stock Surge
Liberty Media Corporation Reaches New 52-Week High Liberty Media Corp (FWONA), a significant player in the media and entertainment sectors, has recently achieved a landmark 52-week high in its stock price, soaring to $75.71. This impressive rise has brought attention to the company's strong market performance, reflecting a substantial gain of 31.03% over the past year....
Continue Reading
Telegram's Pavel Durov Responds to Content Moderation Criticism
Pavel Durov Addresses Concerns Over Telegram's Moderation Pavel Durov, the CEO of Telegram, has recently addressed the growing concerns about the platform’s moderation practices. In a message to his large audience of over 12 million subscribers, Durov pledged that the company would take steps to respond to the criticism regarding how Telegram handles content management....
Continue Reading
FiscalNote Expands Its Reach with New Public Sector Customers
FiscalNote Expands Its Reach with New Public Sector Customers FiscalNote Holdings, Inc. (NYSE: NOTE), renowned for its AI-driven enterprise SaaS technologies, has recently made headlines by securing a myriad of new agreements across the U.S. public sector. These contracts span the federal government's three branches, showcasing the Company's celebrated suite of products...
Continue Reading
Bluejay Diagnostics to Showcase Symphony IL-6 Findings at SAEM
Exciting Announcement from Bluejay Diagnostics Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has recently made a remarkable announcement that will resonate within the medical community. This innovative healthcare company has had an abstract accepted for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting. This significant event is scheduled to take...
Continue Reading
Clean Maine Carbon Launches Biochar Carbon Credits Through Puro.earth
Clean Maine Carbon's Groundbreaking Initiative Clean Maine Carbon (CMC) has taken a significant step forward in sustainable carbon removal by launching its first biochar CO2 Removal Certificates (CORCs). Teaming up with Flowcarbon as its carbon development partner, CMC's move marks a pivotal moment in the quest for innovative solutions to combat climate change. The Role...
Continue Reading